934 related articles for article (PubMed ID: 12365957)
1. Employer drug benefit plans and spending on prescription drugs.
Joyce GF; Escarce JJ; Solomon MD; Goldman DP
JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
[TBL] [Abstract][Full Text] [Related]
2. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
[TBL] [Abstract][Full Text] [Related]
3. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
4. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
Tseng CW; Brook RH; Keeler E; Mangione CM
JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
[TBL] [Abstract][Full Text] [Related]
5. The effect of incentive-based formularies on prescription-drug utilization and spending.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
[TBL] [Abstract][Full Text] [Related]
6. The effect of a three-tier formulary on antidepressant utilization and expenditures.
Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
[TBL] [Abstract][Full Text] [Related]
7. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
Brouwer ED; Basu A; Yeung K
Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
[TBL] [Abstract][Full Text] [Related]
8. Pharmacy benefit spending on oral chemotherapy drugs.
Curtiss FR
J Manag Care Pharm; 2006 Sep; 12(7):570-7. PubMed ID: 16981802
[TBL] [Abstract][Full Text] [Related]
9. Prescription drugs: issues of cost, coverage, and quality.
Copeland C
EBRI Issue Brief; 1999 Apr; (208):1-21. PubMed ID: 10539445
[TBL] [Abstract][Full Text] [Related]
10. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
Klepser DG; Huether JR; Handke LJ; Williams CE
J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
[TBL] [Abstract][Full Text] [Related]
11. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
Haas JS; Phillips KA; Gerstenberger EP; Seger AC
Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
[TBL] [Abstract][Full Text] [Related]
12. Pharmacy benefits and the use of drugs by the chronically ill.
Goldman DP; Joyce GF; Escarce JJ; Pace JE; Solomon MD; Laouri M; Landsman PB; Teutsch SM
JAMA; 2004 May; 291(19):2344-50. PubMed ID: 15150206
[TBL] [Abstract][Full Text] [Related]
13. Impact of brand drug discount cards on private insurer, government and patient expenditures.
Law MR; Chan FKI; Harrison M; Worthington HC
CMAJ; 2019 Nov; 191(45):E1237-E1241. PubMed ID: 31712357
[TBL] [Abstract][Full Text] [Related]
14. Cost reduction strategies used by elderly patients with chronic obstructive pulmonary disease to cope with a generic-only pharmacy benefit.
Spence MM; Hui R; Chan J
J Manag Care Pharm; 2006 Jun; 12(5):377-82. PubMed ID: 16792444
[TBL] [Abstract][Full Text] [Related]
15. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
Clark BE; Siracuse MV; Garis RI
Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
[TBL] [Abstract][Full Text] [Related]
16. Comparing employer-sponsored and federal exchange plans: wide variations in cost sharing for prescription drugs.
Buttorff C; Andersen MS; Riggs KR; Alexander GC
Health Aff (Millwood); 2015 Mar; 34(3):467-76. PubMed ID: 25732498
[TBL] [Abstract][Full Text] [Related]
17. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
Johnson JT; Neill KK; Davis DA
J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
[TBL] [Abstract][Full Text] [Related]
19. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan.
Harris BN; West DS; Johnson J; Hong SH; Stowe CD
J Manag Care Pharm; 2004; 10(5):449-55. PubMed ID: 15369428
[TBL] [Abstract][Full Text] [Related]
20. Impact of multitiered copayments on the use and cost of prescription drugs among Medicare beneficiaries.
Gilman BH; Kautter J
Health Serv Res; 2008 Apr; 43(2):478-95. PubMed ID: 18370964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
